Brief: Neovacs Reports Phase IIb Study Results For IFNalpha Kinoid In The Treatment Of Lupus

Neovacs SA

03/07/2018 06:17

July 3 (Reuters) - NEOVACS SA  ALNEV.PA :
    * NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNALPHA KINOID IN THE TREATMENT
OF
LUPUS
    * HIGHLY STATISTICALLY SIGNIFICANT EFFICACY IN REDUCTION OF INTERFERON SIGNATURE
    * LACK OF STATISTICALLY SIGNIFICANT CLINICAL EFFICACY MEASURED BY BICLA( 1 ) SCORE
    * FAVORABLE SAFETY PROFILE OF IFNALPHA KINOID TREATMENT
    * STATISTICALLY SIGNIFICANT CLINICAL EFFICACY ON LLDAS SCORE
    * PLANS TO SUBMIT FULL RESULTS OF THIS STUDY AND PRESENT THEM AT A FUTURE INTERNATIONAL
SCIENTIFIC
CONGRESS
    * WE ARE VERY PLEASED WITH THESE RESULTS THAT WILL ENABLE US TO MOVE INTO PHASE III WITHIN A
PARTNERING TO BE FINALISED - CEO

Source text for Eikon:  ID:nGNE9r5D68 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))